Market revenue in 2023 | USD 0.1 million |
Market revenue in 2030 | USD 1.3 million |
Growth rate | 47.5% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Sweden live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The live biotherapeutic products and microbiome CDMO market in Sweden has witnessed significant development owing to the presence of a developed biotechnology and healthcare sector. In Sweden, biotechnology and healthcare companies have major goals for the introduction of new drug products benefiting patients.
The increasing number of market players focusing on the acquisition, innovation, and development of new pharmaceutical products contributes to the continuous development of healthcare & improved treatment outcomes. This factor drives the market growth in Sweden.
For instance, in February 2022, Recipharm announced the acquisition of Arranta Bio, an advanced therapy CDMO. The company has established a services portfolio delivering microbiome therapeutic products & mRNA clinical production capabilities.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Sweden live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account